论文部分内容阅读
本刊讯2016年2月12日,欧洲药品管理局(EMA)发布信息称,药物警戒风险评估委员会(PRAC)已完成对钠-葡萄糖2型转运体(SGLT2)抑制剂的审查,并提出使糖尿病酮症酸中毒风险最小化的建议。SGLT2抑制剂是用于治疗2型糖尿病的药物,可以阻断肾脏中被称为SGLT2的蛋白,当血液在肾脏过滤时,这种蛋白可以从尿液中回收葡萄糖进入血液。通过阻断SGLT2的作用,这些药物会导致更多的葡萄糖通过尿液清除,从而降低了血
According to information released by the European Medicines Agency (EMA) on February 12, 2016, PRAC has completed a review of inhibitors of sodium-glucose type 2 transporter (SGLT2) Recommendations for minimizing the risk of diabetic ketoacidosis. The SGLT2 inhibitor, a drug used to treat type 2 diabetes, blocks the protein called SGLT2 in the kidneys, which recovers glucose from the urine into the bloodstream when the blood is filtered through the kidneys. By blocking the action of SGLT2, these drugs cause more glucose to clear through the urine, reducing blood